Dragomir I. Draganov

Dragomir I. Draganov

Auto-generated profile, based on publicly available information

Dragomir I. Draganov

Roche Pharmaceutical Research and Early Development, Pharmaceutical Sciences, F. Hoffmann-La-Roche AG, 4070 Basel, Switzerland

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2015 in Toxicology
Verified
Journal Article
Open access
DDDragomir I. Draganov
Dragomir I. Draganov
DMDan A. Markham
Dan A. Markham
DBDieter Beyer
Dieter Beyer
JWJohn M. Waechter
John M. Waechter
SDStephen S. Dimond
Stephen S. Dimond
SHSteven G. Hentges
Steven G. Hentges
Orally administered bisphenol A (BPA) undergoes efficient first-pass metabolism to produce the inactive conjugates BPA-glucuronide (BPA-G) and BPA-sulfate (BPA-S). This study was conducted to evaluate the pharmacokinetics of BPA, BPA-G and BPA-S in neonatal mice following the administration of a single oral or subcutaneous (SC) dose. This study consisted of 3 phases: (1) mass-balance phase in which effective dose delivery procedures for oral or SC administration of (3)H-BPA to postnatal day three (PND3) mice were developed; (2) pharmacokinetic phase during which systemic exposure to total (3)H-BPA-derived radioactivity in female PND3 mice was established; and (3) metabolite profiling phase in which 50 female PND3 pups received either a single oral or SC dose of (3)H-BPA. Blood was collected from 5 pups/route/time-point at various times post-dosing, the blood plasma samples were pooled by group, and time-point and samples were profiled by HPLC with fraction collection. Fractions were analyzed for total radioactivity and data used to reconstruct radiochromatograms and to integrate individual peaks. The identity of the BPA, BPA-G, and BPA-S peaks was confirmed using authentic standards and LC-MS/MS analysis. The result of this study revealed that female PND3 mice have the capacity to metabolize BPA to BPA-G, BPA-S and other metabolites after both routes of administration. Systemic exposure to free BPA is route-dependent as the plasma concentrations were lower following oral administration compared to SC injection.

25 May 2023 in Drug Discovery Today
Verified
Journal Article
Closed access
TSThomas Steger-Hartmann
Thomas Steger-Hartmann
AKAnnika Kreuchwig
Annika Kreuchwig
KWKen Wang
Ken Wang
FBFabian Birzele
Fabian Birzele
DDDragomir Draganov
Dragomir Draganov
ARAndreas Rothfuss
Andreas Rothfuss